Elinzanetant

GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Elinzanetant is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2025. DrugCentral lists 2 molecular targets, including TACR1 and TACR3. Recorded indications include Vasomotor symptoms due to menopause.

• Approval status: onp (first approved 2025 by the FDA).
• Molecular targets: TACR1 and TACR3 (2 listed in DrugCentral).
• Indications: Vasomotor symptoms due to menopause.
• ATC code: G02CX07 (Other gynecologicals).
• Molecular formula: C33H35F7N4O3; molecular weight 668.66 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Vasomotor symptoms due to menopause

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Substance-P receptor	TACR1	antagonist	Ki 9.45
Neuromedin-K receptor	TACR3	antagonist	Ki 8.40

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2025-11-11	EMA	—	Bayer AG
2025-10-24	FDA	—	Bayer HealthCare Pharmaceuticals Inc.

ATC classification

ATC code	Therapeutic hierarchy
G02CX07	GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Other gynecologicals

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Somnolence	62.1

Chemical structure

• Molecular formula: C₃₃H₃₅F₇N₄O₃
• Molecular weight: 668.66 g/mol
• CAS number: 929046-33-3
• InChIKey: DWRIJNIPBUFCQS-DQEYMECFSA-N
• PubChem CID: 16063568

CC1=C(C=CC(=C1)F)C2=CC(=NC=C2N(C)C(=O)C(C)(C)C3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)N4C[C@H]5COCCN5C[C@H]4CO

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Elinzanetant used for?

DrugCentral lists the following indications for Elinzanetant: Vasomotor symptoms due to menopause.

How does Elinzanetant work?

Its molecular targets in DrugCentral include TACR1 (antagonist) and TACR3 (antagonist).

When was Elinzanetant first approved?

Elinzanetant was first approved by the FDA in 2025.

What is the chemical formula of Elinzanetant?

Elinzanetant has the molecular formula C33H35F7N4O3 and a molecular weight of 668.66 g/mol.

Sources

• DrugCentral drug card 5804 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4802157 — compound record and bioactivity
• PubChem CID 16063568 — chemical identifiers
• FDA UNII NZW2BOW35N — substance identity
• DailyMed: FDA labels for Elinzanetant — current prescribing information (label search)
• UniProt P25103 (TACR1) — target protein
• UniProt P29371 (TACR3) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.